PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jclinpathJournal of Clinical PathologyVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Clin Pathol. 2007 July; 60(7): 808–815.
PMCID: PMC1995780

Extra copies of chromosomes 16 and X in invasive breast carcinomas are related to aggressive phenotype and poor prognosis

Abstract

Background

Breast cancer is a genetically complex disease, which involves the accumulation of various structural and numerical chromosomal aberrations.

Aim

To assess the numerical status of chromosomes 16 and X by interphase cytogenetics, in 114 women with primary invasive breast carcinomas, in relation to clinicopathological parameters, patients' overall survival and indices of cell growth (c‐erbB‐2, topoisomerase IIα (topoIIα)) and cell survival (caspase‐3, bcl‐2).

Experimental design

Chromogenic in situ hybridisation with pericentromeric probes was performed for molecular analysis, while oestrogen and progesterone receptors, cerbB‐2, topoIIα, caspase‐3 and bcl‐2 expression was immunohistochemically detected (ABC/HRP). The results were statistically assessed by univariate and multivariate analyses.

Results

Polysomy of chromosomes 16 and X was detected as the predominant aberration (73.7% and 57.9%, respectively). Gain of chromosome 16 copies was associated with high nuclear grade (p = 0.009), increased tumour size (p = 0.041), advanced stage (p = 0.002), the expression of topoIIα (p = 0.005) and worse overall survival by multivariate analysis (p = 0.032). Chromosome X polysomy was increased in ductal carcinomas of high histological grade (p = 0.008), in high nuclear grade tumours (p = 0.001), and was associated with the expression of topoIIα (p = 0.005), loss of caspase‐3 (p = 0.036) and impaired prognosis of ductal carcinomas (p = 0.041).

Conclusions

Polysomy of chromosomes 16 and X was reported as the predominant alteration in phenotypically aggressive breast tumours, characterised by poor differentiation, increased growth potential and impaired prognosis, whereas gain of chromosome X in particular is probably implicated in cell survival.

Numerical aberrations, including aneusomies (monosomies or polysomies) and changes in ploidy (hypodiploidy or hyperploidy), are frequently found in tumours, including in breast carcinomas, and they are believed to constitute a manifestation of genetic instability.1

Chromosomes 16 and X have been reported to be frequently affected by structural and/or numerical alterations in several forms of malignancies. Chromosomal arm 16q is a region of common loss of heterozygosity (LOH), observed in in situ and invasive tumours of the breast.2,3 This particular region harbours several candidate tumour‐suppressor genes, such as CDH1 (16q22.1), encoding for the E‐cadherin adhesion molecule, which is implicated in the development of invasive lobular carcinomas, and the WWOX/FOR gene (16q23.2–24.1), of which the expression strongly inhibits anchorage‐independent growth in vitro.4,5 Moreover, loss or gain of the entire chromosome 16 has been reported in high‐grade invasive ductal breast carcinomas.6

As far as chromosome X is concerned, several loci of common LOH have been recognised, involving both Xq and Xp,7 and Xq, in particular, is usually lost in breast carcinomas related to oestrogen receptor negativity.2 In addition, over‐representation of chromosome X has been related to lymph node involvement in breast cancer8 and constitutes a recurrent change in non‐Hodgkin's lymphoma and in meningioma tumours in both female and male patients,9,10 whereas loss of the entire X chromosome is observed in invasive ovarian carcinomas.11

Interphase chromogenic in situ hybridisation using pericentromeric probes can be used for chromosome enumeration, as it is generally accepted that gaining or losing of the centromeric region of a chromosome indicates the gain or loss of the entire chromosome.12 Furthermore, due to retention of the tissue architecture, it allows an optimal correlation of the cellular‐level alterations with the phenotypic characteristics, and bypasses the possible problems of dark‐field microscopy.

The purpose of this study was to evaluate the numerical aberrations affecting chromosomes 16 and X in invasive breast cancer, in relation to clinicopathological parameters and patients' recurrence‐free and overall survival. Several biological indices were also included to assess the possible implication of both chromosomes in tumour growth and cell survival.

Materials and methods

Tissue samples

Formalin‐fixed paraffin‐wax‐embedded tissues were obtained from 114 women who had had surgery for primary infiltrating breast cancer. None of them had received radiation or chemotherapy before surgery. The patients' age ranged from 25 to 87 years (mean 56.15 years, median 56 years) and they have been followed‐up at 6‐month intervals, for a median period of 92 months, presenting a mean (range) recurrence‐free and overall survival period of 74.73 (2–114) and 81.99 (5–114) months, respectively. Determination of tissues' pathological features was performed as described previously.13,14

In situ hybridisation

Sections (4 μm thick) were deparaffinised in xylene and pretreated with 30% sodium bisulphate in 2×standard saline citrate. Exposure of the target centromeric DNA sequences was achieved by digestion with proteinase K, followed by a brief rinse in 2×standard saline citrate and dehydration in graded alcohols. Hybridisation with digoxigenin‐labelled pericentromeric probes specific for chromosomes 16 and X (D16Z2 and DXZ1, respectively; Appligene Oncor, Chester‐Le‐Street, Durham, UK) was performed overnight in a humidified chamber, after simultaneous denaturation of chromosomal and probe DNA. Posthybridisation stringent washings were followed by enzymatic detection, using a peroxidase‐conjugated streptavidin antibody, and amplification according to the manufacturer's instructions.

Evaluation of hybridisation signals for each chromosome per neoplastic nucleus was performed by two independent observers using light microscopy with a ×100 planar objective, and was limited to section areas with intact cell morphology and hybridisation signals in at least 80% of cells. For each probe, the counts were expressed as the percentage of nuclei with >2 signals (trisomy, polysomy), with 2 signals (disomy) and with <2 signals (monosomy), resulting from the enumeration of approximately 300 non‐overlapping nuclei per individual tumour. Normal epithelial tissue adjacent to the neoplastic tissue was used as a control for hybridisation sensitivity.

Based on the published data8,12,13,14 and on the evaluation of the signal profile of normal epithelial cells adjacent to the neoplastic tissue (mean value of the control specimens plus three times the SD: nuclei with 1 signal 11% and 9% SD; 2 signals 22% and 15% SD; and [gt-or-equal, slanted]3 signals 8% and 3.5% SD), we concluded that signal loss in >40% of cancer cell nuclei could be safely characterised as monosomy, whereas the presence of >20% of nuclei with signal gain constitutes a reasonable evidence of polysomy.

Immunohistochemistry

The detection of oestrogen and progesterone receptors (ER and PR), c‐erbB‐2, topoisomerase IIα (topoIIα), caspase‐3 and bcl‐2 proteins was performed using a standard avidin‐peroxidase technique. Sections (4 μm Thick) were incubated overnight at 4°C with the following antibodies: anti‐ER clone ID5 and anti‐PR clone 1A6 (Dako, Glostrup, Denmark), anti‐c‐erbB‐2 clone CB11 (Biogenex, San Ramon, California, USA), anti‐topoIIα clone JH2.7 (Biocare Medical, Walnut Creek, California, USA), anti‐caspase‐3 polyclonal antibody (Santa Cruz Biotechnology, California, USA) and anti‐bcl‐2 clone 124 (DAKO, Glostrup, Denmark) in dilutions 1:450, 1:150, 1:150, 1:100, 1:80 and 1:100, respectively.

The cut‐off values used for the evaluation of the expression levels for each protein have already been mentioned elsewhere.15,16,17

Statistical analysis

The possible associations between the percentage of copies of both chromosomes 16 and X and the other assessed parameters were investigated with the Kruskall–Wallis test (histological and nuclear grade, tumour size, stage), the Mann–Whitney U test (menopausal status, histological type, ER, PR, c‐erbB‐2, topoIIα, caspase‐3, bcl‐2) and by analysis of variance. The impact of the numerical status of both chromosomes on postoperative recurrence‐free and overall survival rates was evaluated by univariate (log rank) and multivariate (stepwise forward Cox's proportional hazard regression model) analyses. p[less-than-or-eq, slant]0.05 was considered as significant. The models of multivariate survival analysis included menopausal status, histological type, histological and nuclear grade, tumour size, stage and ER, PR and c‐erbB‐2.

Results

Breast carcinoma tissues demonstrated a heterogenous ploidy pattern consisting of disomic, monosomic and polysomic nuclei, whereas normal epithelium adjacent to the neoplastic compartment contained mainly diploid nuclei populations.

Chromosome 16

Among the 114 cases studied, polysomy of chromosome 16 (fig 1A1A)) was the more frequently found numerical aberration, predominantly expressed in 73.7% (84/114) of the cases, whereas the remaining 21.1% (24/114) and 5.3% (6/114) of the cases were characterised mainly by monosomy (fig 1B1B)) and disomy, respectively. The percentage of chromosome 16 polysomy was significantly associated with nuclear dedifferentiation (p = 0.009; table 11,, fig 2A2A),), increased tumour size (p = 0.041; table 11,, fig 2B2B),), advanced stage of the disease (p = 0.002; table 11,, fig 2C2C)) and the expression of the topoIIα proliferation index (p = 0.005; table 11,, fig 2D2D).). Loss of chromosome 16 copies was correlated with decreased tumour size (p = 0.016; table 11,, fig 2B2B),), lower stage (p = 0.011; table 11,, fig 2C2C),), loss of topoIIα expression (p = 0.016; table 11,, fig 2D2D)) and, moreover, with positive c‐erbB‐2 protein levels (p = 0.012; table 11,, fig 2E2E).). The only significant association observed for chromosome 16 disomy was with tumours of low nuclear grade (p = 0.002; table 11,, fig 2F2F),), whereas aneusomy, in general, was related to increased nuclear grade of breast carcinomas (p = 0.003, fig 2F2F).

figure cp37838.f1
Figure 1 (A) Multiple copies of chromosome 16 in neoplastic nuclei (×300, in situ hybridisation, ISH); (B) neoplastic nuclei with one (monosomy) or two (disomy) hybridisation signals for chromosome 16 (×200, ISH); and (C) breast ...
Table thumbnail
Table 1 Distribution of chromosome 16 copies in relation to clinicopathological parameters and biological indices (Kruskall–Wallis test (histological and nuclear grade, tumour size, stage), Mann–Whitney U test (menopausal status, ...
figure cp37838.f2
Figure 2 Boxplots of the relationships observed between the number of chromosome 16 copies and nuclear grade (A, F), tumour size (B), stage (C), topoIIα (D) and c‐erbB‐2 (E) proteins.

Chromosome X

Polysomy of chromosome X was predominantly found in 57.9% (66/114) of the specimen, while monosomic (fig 1C1C)) and disomic cases represented 35.9% (41/114) and 6.2% (7/114) of the breast cancer tumours studied, respectively. Invasive ductal as well as high nuclear grade carcinomas presented increased levels of chromosome X aneusomy (p = 0.006, fig 3A3A and p<0.001, fig 3B3B,, respectively; table 22).). Furthermore, aneusomy was significantly associated with the expression of c‐erbB‐2 oncoprotein (p = 0.016; table 22,, fig 3C3C)) and with the loss of the apoptosis‐related proteins caspase‐3 and bcl‐2 (p = 0.001, fig 3D3D and p = 0.006, fig 3E3E,, respectively; table 22).). In contrast, the levels of disomy were increased in invasive lobular carcinomas (p = 0.006; table 22,, fig 3A3A)) and low nuclear grade carcinomas (p<0.001; table 22,, fig 3B3B)) and were further related to negative c‐erbB‐2 (p = 0.016; table 22,, fig 3C3C)) and with positive caspase‐3 and bcl‐2 expression (p = 0.001, fig 3D3D and p = 0.006, fig 3E3E,, respectively, table 22).). The levels of chromosome X polysomy, in particular, were elevated in ductal carcinomas of high histological grade (p = 0.008; table 22,, fig 3F3F)) and high nuclear grade tumours (p = 0.001; table 22,, fig 3G3G).). In addition, the percentage of copy gain was related to the expression of topoIIα (p = 0.005; table 22,, fig 3H3H)) and to the loss of caspase‐3 protein (p = 0.036; table 22,, fig 3I3I).). High levels of monosomy for chromosome X were observed in ductal tumours of low histological grade (p = 0.020; table 22,, fig 3F3F),), in low nuclear grade cases (p = 0.041; table 22,, fig 3G3G)) and coincided with absence of topoIIα and c‐erbB‐2 (p = 0.031, fig 3H3H and p = 0.026, fig 3J3J respectively; table 22).).

figure cp37838.f3
Figure 3 Boxplots representing the distribution of chromosome X numerical status in relation to histological type (A), histological grade (F), nuclear grade (B, G), and c‐erbB‐2 (C, J), topoIIα (H), caspase‐3 (D, ...
Table thumbnail
Table 2 Distribution of chromosome X copies in relation to clinicopathological parameters and biological indices (Kruskall–Wallis test (histological and nuclear grade, tumour size, stage), Mann–Whitney U test (menopausal status, ...

Patients' survival

The cases presenting, as the predominant alteration, gain of chromosome 16 copies had the worse overall survival, assessed by univariate (p = 0.017, fig 4A4A)) and multivariate (p = 0.032, hazard ratio (HR) 3.2321, 95% CI 1.1080 to 9.4286) analyses. Similarly, invasive ductal carcinomas with prevalence of chromosome X polysomy presented an impaired outcome, compared with the monosomic cases, assessed by both univariate (p = 0.019, fig 4B4B)) and multivariate (p = 0.041, HR 3.0842, 95% CI 1.0450 to 9.1025) analyses. Patients with invasive lobular carcinoma had no significant difference in their overall survival regarding the number of chromosome X copies (p = 0.312; fig 4C4C).). Among the other parameters included in both multivariate analyses models, only stage was a predictor of impaired prognosis (p<0.001; HR 4.5030, 95% CI 2.3785 to 8.5252 and p<0.001, HR 3.9790, 95% CI 1.8000 to 8.7956, respectively). There was no relationship between the numerical status of either chromosome and recurrence‐free survival of the patients.

figure cp37838.f4
Figure 4 (A) Graphical representation of patients' overall survival according to chromosome 16 numerical status (log rank, Kaplan–Meier); (B) overall survival curves of patients with ductal invasive breast carcinomas according to chromosome ...

Discussion

In the present study, we evaluated the numerical status of chromosomes 16 and X in a group of 114 women with primary invasive breast carcinomas, using an interphase cytogenetic approach. Aneusomy, and more specifically polysomy, of both chromosomes was the predominant ploidy pattern in most cases. A similar pattern for chromosome 16 copies has been reported in invasive ductal carcinomas of the breast,6 whereas chromosome X polysomy was the most frequently found aberration in invasive carcinomas of the breast and of the cervix uteri8,18 and in non‐Hodgkin's lymphomas.9

Deviations of both chromosomes from the normal disomic complement were associated with aggressive phenotypic features of breast tumours such as advanced stage, larger tumour size, high nuclear and histological grade, as has already been mentioned for in situ and invasive ductal carcinomas of the breast8,19 and cervical intraepithelial neoplasia,18 probably reflecting groups of breast cancers with different cytogenetics and biologies.2 The above‐mentioned findings indicate an implication of both chromosomes with breast cancer progression and they may reflect a more widespread accumulation of genetic changes, due to increased genomic destabilisation inherent to a more aggressive form of malignancy.

A novel observation of this study is the statistically independent relationship with survival of impaired patients. Prevalence of chromosome 16 polysomy was found to be a predictor of shortened overall survival irrespective of the histology of the tumour, whereas chromosome X polysomy was a factor of adverse prognosis specifically for ductal carcinomas. This restriction of the prognostic significance of chromosome X to the ductal breast tumours could be attributed to the observed relationship between aneusomy of this chromosome with this specific histological subtype, whereas the lobular carcinomas included in our study consisted mainly of disomic nuclei populations, probably reflecting the presence of distinct oncogenetic pathways between tumours of the ductal and lobular histological type.

The numerical status of both chromosomes seems to have a direct implication on cell growth, as suggested by the relationships with the expression of topoIIα and c‐erbB‐2 proteins, a finding mentioned for the first time, to our knowledge. Gain of centromeric signals for both chromosomes predominated in topoIIα‐expressing cells, whereas the levels of chromosome X aneusomy were also associated with the expression of c‐erbB‐2 protein. Interestingly, chromosome 16 monosomy presented a parallel relationship with c‐erbB‐2 and an inverse one with topoIIα protein. TopoIIα is a key regulatory protein in DNA replication and is considered as an indicator of tumour cell proliferation, as it is mainly expressed during the S phase of the cell cycle20 and in phenotypically aggressive breast tumours.15 Overexpression of c‐erbB‐2 may result in a shortening of the G1 phase of the cell cycle and early entry to S phase, which leads to hyperproliferation in breast luminal epithelial cells.21 Furthermore, due to the physical proximity of topoIIα and c‐erbB‐2 gene loci on chromosome 17, it has been reported, in certain cases, to be co‐amplified along with the highly recurrent 17q gain, which results in the overexpression of c‐erbB‐2 oncoprotein,20,22 observed in most breast carcinomas with increased malignant potential.16 According to Jarvinen et al,22 a physical deletion of topoIIα gene also occurs, even before hyperploidisation of the tumour in c‐erbB‐2‐amplified breast cancer cell lines, and is associated with decreased levels of topoIIα protein expression. Our suggestion regarding a probable relationship of chromosomes 16 and X with cellular proliferation derives further support from the fact that both chromosomes harbour genes implicated in tumour growth, including genes CTCF, SEN16 and Glypican 3.23,24,25

Of special interest is the observation of a possible involvement of chromosome X aneusomy with apoptosis. The inverse relationship with caspase‐3 may be partly supported by the presence on chromosome X of the gene encoding the X‐linked inhibitor of apoptosis protein, which specifically binds and inhibits the function of caspase‐3, 7 and 9, and is found overexpressed in cancer cell lines, providing a survival advantage.26 The absence of expression of bcl‐2 protein in tumours with increased levels of chromosome X gain at first may seem controversial due to the fact that caspase‐3 is an inducer of apoptosis, whereas bcl‐2 is an antiapoptotic protein which acts as a regulator of caspase‐3. Despite that, Fujita et al27 report that caspase‐3 has the ability, at least in the case of VP‐16‐induced U937 cell apoptosis, to modulate the function of bcl‐2 by cleaving it to a shorter truncated form, which is pro‐apoptotic in contrast with the longer anti‐apoptotic form.

In our study, monosomy coincided with rather less aggressive features. This finding is probably unsustained, given the extensive lack of genetic material, which leads to alterations, or even silencing of numerous genes. Several studies focusing on structural chromosomal aberrations propose that certain losses of genetic segments may in fact correlate with more favourable prognostic features. In a cytogenetic and DNA flow cytometric analysis of a series of breast carcinomas, the loss of the long arm of chromosome 16 was significantly associated with low S phase fraction.28 LOH of 16q in breast cancer has been reported to be present in low‐grade non‐invasive and invasive breast carcinomas.2,6 In addition, allelic loss of 16q23.2–24.2 has been reported to be an independent predictor of good disease‐free and overall prognosis in primary breast cancer.29 The reports concerning structural alterations of chromosome X provide compelling results, which are further complicated due to the random inactivation of one X chromosome in every cell in females 30 and the fact that up to 30 genes are known to escape X chromosome inactivation.31 Although LOH in the proximal portion of the inactive Xq, overlapping the AR locus (Xq11–12), it has been described to be important for the control of ovarian tumours of low malignant potential,11 an Xq25 loss of the inactive X chromosome in breast carcinomas has been related to increased tumour size, lymph nodal involvement and poor differentiation.32

Take‐home messages

  • Numerical chromosome aberrations (monosomies, polysomies) are frequently found in breast carcinomas by conventional karyotypic analysis and interface in situ hybridisation technique.
  • Polysomy of chromosome 16 was the predominant alteration in phenotypically aggressive breast tumours, affecting patients' survival negatively, while monosomy correlated with tumours of less‐aggressive features.
  • Polysomy of chromosome X was more frequently detected in less‐differentiated invasive ductal carcinomas exerting unfavourable impact on prognosis.

In the present study, polysomy of chromosomes 16 and X was present as the predominant alteration in phenotypically aggressive breast cancer tumours, characterised by poor differentiation, increased growth potential and impaired outcome, whereas gain of chromosome X, in particular, is probably implicated in cell survival. In contrast, monosomy especially in the case of chromosome 16 was related to a prognostically more favourable phenotype, indicating that loss of chromosome 16 copies may constitute an early event in breast carcinogenesis.

Acknowledgements

We thank Mr John Mavrommatis for his contribution to the realisation of this study. This study was financially supported by the Greek Ministry of Development.

Abbreviations

LOH - loss of heterozygosity

topoIIα - topoisomerase IIα

Footnotes

Competing interests: None declared.

References

1. Dutrillaux B, Gerbault‐Seureau M, Remvikos Y. et al Breast cancer genetic evolution: I. Data from cytogenetics and DNA content. Breast Cancer ResTreat1991. 19245–255.255
2. Roylance R, Gorman P, Harris W. et al Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 1999. 591433–1436.1436 [PubMed]
3. Tirkkonen M, Tanner M, Karhu R. et al Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 1998. 21177–184.184 [PubMed]
4. Berry G, Cleton‐Jansen A M, Strumane K. et al E‐cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996. 131919–1925.1925 [PubMed]
5. Bedharek A K, Keck‐Waggoner C L, Daniel R L. et al WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 2001. 618068–8073.8073 [PubMed]
6. Tsuda H, Takarabe T, Hirohashi S. Correlation of numerical and structural status of chromosome 16 with histological type and grade of non‐invasive and invasive breast carcinomas. Int J Cancer (Prd Oncol) 1999. 84381–387.387
7. Loupart M L, Adams S, Armour J A. et al Loss of heterozygosity on the X‐chromosome in human breast cancer. Genes Chromosomes Cancer 1995. 13229–238.238 [PubMed]
8. Persons D L, Robinson R A, Hsu P H. et al Chromosome‐specific aneusomy in carcinoma of the breast. Clin Cancer Res 1996. 2883–888.888 [PubMed]
9. Renedo M, Martinez‐Delgado B, Arranz E. et al Chromosomal changes pattern and gene amplification in T cell non‐Hodgkin's lymphomas. Leukemia 2001. 151627–1632.1632 [PubMed]
10. Sayagues J M, Tabernero M D, Maillo A. et al Incidence of numerical chromosome aberrations in meningioma tumors as revealed by fluorescence in situ hybridization using 10 chromosome‐specific probes. Cytometry 2002. 50153–159.159 [PubMed]
11. Cheng P C, Gosewehr J A, Kim T M. et al Potential role of the inactivated X chromosome in ovarian epithelial tumor development.J Natl Cancer Inst 1996. 88510–518.518 [PubMed]
12. Murphy D S, Hoare S F, Going J J. et al Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J Natl Cancer Inst 1995. 871694–1704.1704 [PubMed]
13. Visscher D, Jimenez R E, Grayson M., 3rd et al Histopathologic analysis of chromosome aneuploidy in ductal carcinoma of in situ. Hum Pathol 2000. 31201–207.207 [PubMed]
14. Visscher D W, Wallis T L, Crissman J D. Evaluation of chromosome aneuploidy in tissue sections of preinvasive breast carcinomas using interphase cytogenetics. Cancer 1996. 77315–320.320 [PubMed]
15. Nakopoulou L, Lazaris A C, Kavantzas N. et al DNA topoisomerase II alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 2000. 68137–143.143 [PubMed]
16. Nakopoulou L, Alexiadou A, Theodoropoulos G E. et al Prognostic significance of the co‐expression of p53 and c‐erbB‐2 proteins in breast cancer. J Pathol 1996. 17931–38.38 [PubMed]
17. Nakopoulou L, Alexandrou P, Stefanaki K. et al Immunohistochemical expression of caspase‐3 as an adverse indicator of the clinical outcome in human breast cancer. Pathobiology 2001. 69266–273.273 [PubMed]
18. Bulten J, Poddighe P J, Roben J C M. et al Interphase cytogenetic analysis of cervical intraepithelial neoplasia. Am J Pathol 1998. 152495–503.503 [PubMed]
19. Schwendel A, Richard F, Langreck H. et al Chromosome alterations in breast carcinomas: frequent involvement of DNA losses including chromosomes 4q and 21q. Br J Cancer 1998. 78806–811.811 [PMC free article] [PubMed]
20. Jarvinen T A, Kononen J, Pelto‐Huikko M. et al Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy, and c‐erbB‐2 overexpression in breast cancer. Am J Pathol 1996. 1482073–2082.2082 [PubMed]
21. Timms J F, White S L, O' Hare M J. et al Effects of ErbB‐2 overexpression on mitogenic signaling and cycle progression in human breast luminal epithelial cells. Oncogene 2002. 216573–6586.6586 [PubMed]
22. Hulit J, Lee R J, Russell R G. et al ErbB‐2‐induced mammary tumor growth: the role of cyclin D1 and p27Kip1. Biochem Pharmacol 2002. 64827–836.836 [PubMed]
23. Filippova G M, Lindblom A, Meincke L J. et al A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancer. Genes ChromosomesCancer1998. 2226–36.36
24. Reddy D E, Sandhu A K, de Riel J K. et al Identification of a gene at 16q24.3 that restores cellular senescence in immortal mammary tumor cells. Oncogene 1999. 185100–5117.5117 [PubMed]
25. Xiang Y Y, Ladeda V, Filmus H. Glypican‐3 expression is silenced in human breast cancer. Oncogene 2001. 207408–7412.7412 [PubMed]
26. Fong W G, Liston P, Rajcan‐Separovic E. et al Expression and genetic analysis of XIAP‐associated factor‐1 (XAF1) in cancer cell lines. Genomics 2000. 15113–122.122 [PubMed]
27. Fujita N, Tsumo T. Involvement of bcl‐2 cleavage in the acceleration of VP‐16‐induced U937 cell apoptosis. Biochem Biophys Res Commun 1998. 246484–488.488 [PubMed]
28. Adeyinka A, Baldetorp B, Mertens F. et al Comparative cytogenetic and DNA flow cytometric analysis of 242 primary breast carcinomas. Cancer GenetCytogenet2003. 14762–67.67
29. Hansen L L, Vilmaz M, Overgaard J. et al Allelic loss of 16q23.2–24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res 1998. 582166–2169.2169 [PubMed]
30. Lyon M F. The William Allan Memorial Award address: X‐chromosome inactivation and the location and expression of X‐linked genes. Am J HumGenet1988. 428–16.16
31. Miller A P, Willard H F. Chromosomal basis of X chromosome inactivation: identification of a multigene domain in Xp11.21–p11.22 that escapes X inactivation. Proc Natl Acad Sci USA 1998. 958709–8714.8714 [PubMed]
32. Piao Z, Malkhosyan S R. Frequent loss Xq25 on the inactive X chromosome in primary breast carcinomas is associated with tumor grade and axillary lymph node metastasis. Genes Chromosomes Cancer 2002. 33262–269.269 [PubMed]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Group